Sildenafil Citrate and Uteroplacental Perfusion in Fetal Growth Restriction

Document Type : Original Article

Authors

Obstetrics and Gynecology Department, Faculty of Medicine, Ain Shams University

Abstract

Background: Severe early-onset fetal growth restriction can lead to a range of adverse outcomes including fetal or neonatal death, neurodisability, and lifelong risks to the health of the affected child. Sildenafil, a phosphodiesterase type 5 inhibitor, potentiates the actions of nitric oxide, which leads to vasodilatation of the uterine vessels and might improve fetal growth in utero.
Objective: To evaluate effectiveness and safety of Sildenafil citrate for treatment of intrauterine growth restriction (IUGR). Design: A prospective randomized control study.
Setting: At Ain shams University hospital and Kafr Aldwwar main Hospital in El-Beheria governorate. Subjects: Eighty pregnant women with gestational age between 24 and 34 weeks having singleton pregnancy and suffering from IUGR attending an antenatal clinic.
Methods: Eighty pregnant women with FGR and abnormal umbilical artery Doppler between 24and34 weeks were randomly allocated to sildenafil (n= 40) 25mg tid or placebo (n=40) with a plenty of fluids until delivery. Main outcome measure: Length of pregnancy, neonatal weight and ICU admission.
Results: Sildenafil treatment was associated with a significant increase in length of pregnancy (P> 0.05) and a significant increase in estimated fetal weight by ultrasound (P<0.05), and was associated with a significant decrease in neonatal ICU admission (P=0.218) and neonatal mortality (P=0.290).
Conclusion: Sildenafil citrate can improve utero-placental perfusion and length of pregnancy in pregnancies complicated by IUGR. It appears to have a significantly positive effect on fetal weight. Sildenafil treatment may offer a new opportunity to improve perinatal outcomes, for pregnancies complicated by IUGR. However these observations require further studies on wide scale.

Keywords